Ex-Genzyme chief's $10M gift kicks off MGH cancer center

Biotech pioneer Henri Termeer (photo) can now add a startup to his resume. After recently retiring from Genzyme in the wake of the big Sanofi ($SNY) buyout, Termeer is seeding the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital with a $10 million donation. Report

Suggested Articles

Several of the industry's top players had a strong performance in the fourth quarter, growing revenues at high single digits. Others? Not so much.

Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.